MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 - Germany

This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

CodeSystem: MII CodeSystem Onkologie - Weitere Klassifikationen oBDS

Official URL: https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-weitere-klassifikationen-obds Version: 2027.0.0-ballot.1
Active as of 2026-09-15 Computable Name: MII_CS_Onko_Weitere_Klassifikationen_OBDS

oBDS-specific classification systems and scoring systems not yet covered by international terminologies (SNOMED CT, NCI Thesaurus). These codes supplement the existing ValueSet for additional classifications. Research required: Check if SNOMED CT or LOINC codes exist for these scoring systems before using oBDS-specific codes.

This Code system is referenced in the definition of the following value sets:

This case-sensitive code system https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-weitere-klassifikationen-obds defines the following codes in an undefined hierarchy:

LvlCodeDisplayDefinition
1 binet BINET Staging System Staging system for chronic lymphocytic leukemia based on lymph node involvement and organ enlargement.
2   binet-a BINET A Early stage CLL: lymphocytosis in blood and bone marrow only
2   binet-b BINET B Intermediate stage CLL: lymphocytosis with enlarged lymph nodes or spleen/liver
2   binet-c BINET C Advanced stage CLL: lymphocytosis with anemia or thrombocytopenia
1 ann-arbor-stadium Ann-Arbor Stadium Staging system for Hodgkin and Non-Hodgkin lymphomas based on anatomical extent of disease.
2   ann-arbor-i I Single lymph node region or single extralymphatic organ
2   ann-arbor-ia IA Single lymph node region, asymptomatic
2   ann-arbor-iae IAE Single lymph node region with extranodal extension, asymptomatic
2   ann-arbor-ib IB Single lymph node region with B symptoms
2   ann-arbor-ibe IBE Single lymph node region with extranodal extension and B symptoms
2   ann-arbor-ie IE Single extralymphatic organ involvement
2   ann-arbor-ix IX Single lymph node region, symptoms unclear
2   ann-arbor-ixa IXA Single lymph node region, symptoms unclear, asymptomatic features
2   ann-arbor-ixae IXAE Single lymph node region with extranodal extension, symptoms unclear, asymptomatic features
2   ann-arbor-ixb IXB Single lymph node region, symptoms unclear, B symptom features
2   ann-arbor-ixbe IXBE Single lymph node region with extranodal extension, symptoms unclear, B symptom features
2   ann-arbor-ixe IXE Single extralymphatic organ, symptoms unclear
2   ann-arbor-ii II Two or more lymph node regions on same side of diaphragm
2   ann-arbor-ii1 II1 Two lymph node regions on same side of diaphragm
2   ann-arbor-ii1a II1A Two lymph node regions on same side of diaphragm, asymptomatic
2   ann-arbor-ii1ae II1AE Two lymph node regions on same side of diaphragm with extranodal extension, asymptomatic
2   ann-arbor-ii1b II1B Two lymph node regions on same side of diaphragm with B symptoms
2   ann-arbor-ii1be II1BE Two lymph node regions on same side of diaphragm with extranodal extension and B symptoms
2   ann-arbor-ii1e II1E Two lymph node regions on same side of diaphragm with extranodal extension
2   ann-arbor-ii1x II1X Two lymph node regions on same side of diaphragm, symptoms unclear
2   ann-arbor-ii1xa II1XA Two lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features
2   ann-arbor-ii1xae II1XAE Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features
2   ann-arbor-ii1xb II1XB Two lymph node regions on same side of diaphragm, symptoms unclear, B symptom features
2   ann-arbor-ii1xbe II1XBE Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features
2   ann-arbor-ii1xe II1XE Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear
2   ann-arbor-ii2 II2 Multiple lymph node regions on same side of diaphragm
2   ann-arbor-ii2a II2A Multiple lymph node regions on same side of diaphragm, asymptomatic
2   ann-arbor-ii2ae II2AE Multiple lymph node regions on same side of diaphragm with extranodal extension, asymptomatic
2   ann-arbor-ii2b II2B Multiple lymph node regions on same side of diaphragm with B symptoms
2   ann-arbor-ii2be II2BE Multiple lymph node regions on same side of diaphragm with extranodal extension and B symptoms
2   ann-arbor-ii2e II2E Multiple lymph node regions on same side of diaphragm with extranodal extension
2   ann-arbor-ii2x II2X Multiple lymph node regions on same side of diaphragm, symptoms unclear
2   ann-arbor-ii2xa II2XA Multiple lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features
2   ann-arbor-ii2xae II2XAE Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features
2   ann-arbor-ii2xb II2XB Multiple lymph node regions on same side of diaphragm, symptoms unclear, B symptom features
2   ann-arbor-ii2xbe II2XBE Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features
2   ann-arbor-ii2xe II2XE Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear
2   ann-arbor-iia IIA Two or more lymph node regions on same side of diaphragm, asymptomatic
2   ann-arbor-iiae IIAE Two or more lymph node regions on same side of diaphragm with extranodal extension, asymptomatic
2   ann-arbor-iib IIB Two or more lymph node regions on same side of diaphragm with B symptoms
2   ann-arbor-iibe IIBE Two or more lymph node regions on same side of diaphragm with extranodal extension and B symptoms
2   ann-arbor-iie IIE Two or more lymph node regions on same side of diaphragm with extranodal extension
2   ann-arbor-iix IIX Two or more lymph node regions on same side of diaphragm, symptoms unclear
2   ann-arbor-iixa IIXA Two or more lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features
2   ann-arbor-iixae IIXAE Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features
2   ann-arbor-iixb IIXB Two or more lymph node regions on same side of diaphragm, symptoms unclear, B symptom features
2   ann-arbor-iixbe IIXBE Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features
2   ann-arbor-iixe IIXE Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear
2   ann-arbor-iii III Lymph node regions on both sides of diaphragm
2   ann-arbor-iiia IIIA Lymph node regions on both sides of diaphragm, asymptomatic
2   ann-arbor-iiiae IIIAE Lymph node regions on both sides of diaphragm with extranodal extension, asymptomatic
2   ann-arbor-iiiaes IIIAES Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, asymptomatic
2   ann-arbor-iiias IIIAS Lymph node regions on both sides of diaphragm with spleen involvement, asymptomatic
2   ann-arbor-iiib IIIB Lymph node regions on both sides of diaphragm with B symptoms
2   ann-arbor-iiibe IIIBE Lymph node regions on both sides of diaphragm with extranodal extension and B symptoms
2   ann-arbor-iiibes IIIBES Lymph node regions on both sides of diaphragm with extranodal extension, spleen involvement, and B symptoms
2   ann-arbor-iiibs IIIBS Lymph node regions on both sides of diaphragm with spleen involvement and B symptoms
2   ann-arbor-iiie IIIE Lymph node regions on both sides of diaphragm with extranodal extension
2   ann-arbor-iiies IIIES Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement
2   ann-arbor-iiis IIIS Lymph node regions on both sides of diaphragm with spleen involvement
2   ann-arbor-iiix IIIX Lymph node regions on both sides of diaphragm, symptoms unclear
2   ann-arbor-iiixa IIIXA Lymph node regions on both sides of diaphragm, symptoms unclear, asymptomatic features
2   ann-arbor-iiixae IIIXAE Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear, asymptomatic features
2   ann-arbor-iiixaes IIIXAES Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear, asymptomatic features
2   ann-arbor-iiixas IIIXAS Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear, asymptomatic features
2   ann-arbor-iiixb IIIXB Lymph node regions on both sides of diaphragm, symptoms unclear, B symptom features
2   ann-arbor-iiixbe IIIXBE Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear, B symptom features
2   ann-arbor-iiixbes IIIXBES Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear, B symptom features
2   ann-arbor-iiixbs IIIXBS Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear, B symptom features
2   ann-arbor-iiixe IIIXE Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear
2   ann-arbor-iiixes IIIXES Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear
2   ann-arbor-iiixs IIIXS Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear
2   ann-arbor-iii1 III1 Limited lymph node regions on both sides of diaphragm
2   ann-arbor-iii1a III1A Limited lymph node regions on both sides of diaphragm, asymptomatic
2   ann-arbor-iii1b III1B Limited lymph node regions on both sides of diaphragm with B symptoms
2   ann-arbor-iii2 III2 Multiple lymph node regions on both sides of diaphragm
2   ann-arbor-iii2a III2A Multiple lymph node regions on both sides of diaphragm, asymptomatic
2   ann-arbor-iii2b III2B Multiple lymph node regions on both sides of diaphragm with B symptoms
2   ann-arbor-iv IV Disseminated involvement of one or more extralymphatic organs
2   ann-arbor-iva IVA Disseminated involvement of extralymphatic organs, asymptomatic
2   ann-arbor-ivae IVAE Disseminated involvement of extralymphatic organs with additional extranodal extension, asymptomatic
2   ann-arbor-ivb IVB Disseminated involvement of extralymphatic organs with B symptoms
2   ann-arbor-ivbe IVBE Disseminated involvement of extralymphatic organs with additional extranodal extension and B symptoms
2   ann-arbor-ive IVE Disseminated involvement of extralymphatic organs with extranodal extension
2   ann-arbor-ivx IVX Disseminated involvement of extralymphatic organs, symptoms unclear
2   ann-arbor-ivxa IVXA Disseminated involvement of extralymphatic organs, symptoms unclear, asymptomatic features
2   ann-arbor-ivxae IVXAE Disseminated involvement of extralymphatic organs with additional extranodal extension, symptoms unclear, asymptomatic features
2   ann-arbor-ivxb IVXB Disseminated involvement of extralymphatic organs, symptoms unclear, B symptom features
2   ann-arbor-ivxbe IVXBE Disseminated involvement of extralymphatic organs with additional extranodal extension, symptoms unclear, B symptom features
2   ann-arbor-ivxe IVXE Disseminated involvement of extralymphatic organs with extranodal extension, symptoms unclear
1 iss International Staging System Staging system for multiple myeloma based on serum beta-2 microglobulin and albumin levels.
2   iss-i ISS I Beta-2 microglobulin <3.5 mg/L and albumin ≥3.5 g/dL
2   iss-ii ISS II Not ISS I or ISS III
2   iss-iii ISS III Beta-2 microglobulin ≥5.5 mg/L
1 isswm International Scoring System for Waldenström's Macroglobulinemia Prognostic scoring system for Waldenström's macroglobulinemia based on age, beta-2 microglobulin, and albumin levels.
2   isswm-n ISSWM Niedrig Low risk: age ≤65 years, beta-2 microglobulin ≤3 mg/L, albumin >3.5 g/dL
2   isswm-i ISSWM Intermediär Intermediate risk: one adverse factor
2   isswm-h ISSWM Hoch High risk: age >65 years or beta-2 microglobulin >3 mg/L, or albumin ≤3.5 g/dL (≥2 factors)
1 who-grad WHO Grade World Health Organization grading system for central nervous system tumors based on histological features.
2   who-grad-i WHO Grad I Well-differentiated, slow-growing, low proliferative potential
2   who-grad-ii WHO Grad II Moderately differentiated, infiltrative, low proliferative potential
2   who-grad-iii WHO Grad III Poorly differentiated, anaplastic, high proliferative potential
2   who-grad-iv WHO Grad IV Poorly differentiated, high mitotic activity, necrosis, microvascular proliferation
1 formen Formen Classification of lymphoma forms distinguishing classical and variant presentations.
2   formen-k Klassisch Classical form of lymphoma presentation
2   formen-v Variante Variant form of lymphoma presentation
1 eln-klassifikation ELN-Klassifikation European LeukemiaNet risk stratification for acute myeloid leukemia based on cytogenetic and molecular genetic abnormalities.
2   eln-g ELN Günstig Favorable risk: good prognosis cytogenetic/molecular markers
2   eln-i1 ELN Intermediär I Intermediate risk I: intermediate prognosis markers
2   eln-i2 ELN Intermediär II Intermediate risk II: intermediate prognosis markers
2   eln-u ELN Ungünstig Unfavorable risk: poor prognosis cytogenetic/molecular markers
2   eln-cp ELN Chronische Phase Chronic phase (CML context)
2   eln-ap ELN Akzelierte Phase Accelerated phase (CML context)
2   eln-bk ELN Blastenkrise Blast crisis phase (CML context)
1 durie-salmon-stadium Durie-Salmon Stadium Multiple myeloma staging system based on tumor burden and organ function.
2   durie-salmon-i Durie-Salmon I Low tumor burden: hemoglobin >10 g/dL, calcium normal, no bone lesions
2   durie-salmon-ia Durie-Salmon IA Low tumor burden with normal renal function
2   durie-salmon-ib Durie-Salmon IB Low tumor burden with abnormal renal function
2   durie-salmon-ii Durie-Salmon II Intermediate tumor burden: neither stage I nor III criteria
2   durie-salmon-iia Durie-Salmon IIA Intermediate tumor burden with normal renal function
2   durie-salmon-iib Durie-Salmon IIB Intermediate tumor burden with abnormal renal function
2   durie-salmon-iii Durie-Salmon III High tumor burden: hemoglobin <8.5 g/dL, calcium elevated, extensive bone lesions
2   durie-salmon-iiia Durie-Salmon IIIA High tumor burden with normal renal function
2   durie-salmon-iiib Durie-Salmon IIIB High tumor burden with abnormal renal function
1 figo FIGO Staging system of the International Federation of Gynecology and Obstetrics (FIGO) for gynecological malignancies.
2   figo-i FIGO I Tumor confined to the organ of origin
2   figo-ia FIGO IA Stage I with limited local extent (entity-specific definition)
2   figo-ia1 FIGO IA1 Stage IA, subgroup 1 (e.g. cervix: measured stromal invasion <3 mm)
2   figo-ia2 FIGO IA2 Stage IA, subgroup 2 (e.g. cervix: measured stromal invasion 3 to <5 mm)
2   figo-ia3 FIGO IA3 Stage IA, subgroup 3 (entity-specific definition)
2   figo-ib FIGO IB Stage I with extended local extent (entity-specific definition)
2   figo-ib1 FIGO IB1 Stage IB, subgroup 1 (e.g. cervix: invasive carcinoma <2 cm)
2   figo-ib2 FIGO IB2 Stage IB, subgroup 2 (e.g. cervix: invasive carcinoma 2 to <4 cm)
2   figo-ib3 FIGO IB3 Stage IB, subgroup 3 (e.g. cervix: invasive carcinoma 4 cm or larger)
2   figo-ic FIGO IC Stage I with capsule rupture, surface involvement or malignant ascites
2   figo-ic1 FIGO IC1 Stage IC due to intraoperative surgical spill
2   figo-ic2 FIGO IC2 Stage IC due to preoperative capsule rupture or surface tumor
2   figo-ic3 FIGO IC3 Stage IC due to malignant cells in ascites or peritoneal washings
2   figo-ii FIGO II Tumor extending beyond the organ of origin within the pelvis
2   figo-iia FIGO IIA Stage II with limited extension (entity-specific definition)
2   figo-iia1 FIGO IIA1 Stage IIA, subgroup 1 (e.g. cervix: lesion <4 cm)
2   figo-iia2 FIGO IIA2 Stage IIA, subgroup 2 (e.g. cervix: lesion 4 cm or larger)
2   figo-iib FIGO IIB Stage II with extended extension (entity-specific definition)
2   figo-iic FIGO IIC Stage II with capsule rupture, surface involvement or malignant ascites (historical FIGO revisions)
2   figo-iii FIGO III Tumor with extrapelvic peritoneal spread and/or regional lymph node involvement
2   figo-iiia FIGO IIIA Stage III with microscopic or limited extrapelvic spread (entity-specific definition)
2   figo-iiia1 FIGO IIIA1 Stage III with retroperitoneal lymph node metastasis only
2   figo-iiia1i FIGO IIIA1(i) Stage IIIA1 with lymph node metastasis 10 mm or smaller
2   figo-iiia1ii FIGO IIIA1(ii) Stage IIIA1 with lymph node metastasis larger than 10 mm
2   figo-iiia2 FIGO IIIA2 Stage III with microscopic extrapelvic peritoneal involvement
2   figo-iiib FIGO IIIB Stage III with macroscopic extrapelvic peritoneal metastasis 2 cm or smaller
2   figo-iiic FIGO IIIC Stage III with macroscopic extrapelvic peritoneal metastasis larger than 2 cm and/or regional lymph node metastasis
2   figo-iiic1 FIGO IIIC1 Stage III with pelvic lymph node metastasis
2   figo-iiic1r FIGO IIIC1r Stage IIIC1 established by imaging
2   figo-iiic1p FIGO IIIC1p Stage IIIC1 established by pathology
2   figo-iiic2 FIGO IIIC2 Stage III with para-aortic lymph node metastasis
2   figo-iiic2r FIGO IIIC2r Stage IIIC2 established by imaging
2   figo-iiic2p FIGO IIIC2p Stage IIIC2 established by pathology
2   figo-iv FIGO IV Distant metastasis beyond the peritoneal cavity
2   figo-iva FIGO IVA Stage IV with spread to adjacent pelvic organs or pleural effusion with positive cytology (entity-specific definition)
2   figo-ivb FIGO IVB Stage IV with distant metastasis including extra-abdominal organs and lymph nodes
2   figo-ivc FIGO IVC Stage IV with distant metastasis (entity-specific definition)
1 bismuth Bismuth Classification system for hilar cholangiocarcinoma based on the extent of biliary involvement and resectability.
2   bismuth-i Bismuth I Tumor below confluence of left and right hepatic ducts
2   bismuth-ii Bismuth II Tumor reaching confluence but not involving secondary ducts
2   bismuth-iii Bismuth III Tumor involving confluence and either right or left secondary ducts
2   bismuth-iiia Bismuth IIIA Tumor involving confluence and right secondary ducts
2   bismuth-iiib Bismuth IIIB Tumor involving confluence and left secondary ducts
2   bismuth-iv Bismuth IV Tumor involving confluence and both right and left secondary ducts
1 masaoka Masaoka Staging system for thymomas based on invasiveness and extent of disease.
2   masaoka-i Masaoka I Encapsulated tumor without invasion
2   masaoka-ii Masaoka II Invasion into surrounding fatty tissue or mediastinal pleura
2   masaoka-iii Masaoka III Invasion into neighboring organs
2   masaoka-iv Masaoka IV Pleural or pericardial dissemination
2   masaoka-iva Masaoka IVA Pleural or pericardial implants
2   masaoka-ivb Masaoka IVB Lymphogenous or hematogenous metastasis
1 mitoserate-gist Mitoserate-GIST Mitotic rate assessment for gastrointestinal stromal tumors.
2   mitoserate-gist-n Mitoserate-GIST Niedrig Low mitotic rate: ≤5 mitoses per 50 HPF
2   mitoserate-gist-h Mitoserate-GIST Hoch High mitotic rate: >5 mitoses per 50 HPF
1 p16 p16 p16 protein expression status assessment.
2   p16-p p16 Positiv Positive p16 protein expression
2   p16-n p16 Negativ Negative p16 protein expression
1 eutos-score EUTOS-Score European Treatment and Outcome Study prognostic score for chronic myeloid leukemia.
2   eutos-score-n EUTOS-Score Niedrigrisiko Low risk EUTOS score: ≤87
2   eutos-score-h EUTOS-Score Hochrisiko High risk EUTOS score: >87
1 sanz-score Sanz-Score Risk assessment score for acute promyelocytic leukemia.
2   sanz-score-n Sanz-Score Niedrig Low risk: WBC <10x10⁹/L and platelets >40x10⁹/L
2   sanz-score-i Sanz-Score Intermediär Intermediate risk: WBC <10x10⁹/L and platelets ≤40x10⁹/L
2   sanz-score-h Sanz-Score Hoch High risk: WBC ≥10x10⁹/L
1 ipi IPI International Prognostic Index for aggressive non-Hodgkin lymphoma.
2   ipi-n IPI Niedrig Low risk: 0-1 risk factors
2   ipi-ni IPI Niedrig-Intermediär Low-intermediate risk: 2 risk factors
2   ipi-hi IPI Hoch-Intermediär High-intermediate risk: 3 risk factors
2   ipi-h IPI Hoch High risk: 4-5 risk factors
1 flipi FLIPI Follicular Lymphoma International Prognostic Index.
2   flipi-l FLIPI Low risk Low risk: 0-1 risk factors
2   flipi-i FLIPI Intermediate risk Intermediate risk: 2 risk factors
2   flipi-h FLIPI High risk High risk: ≥3 risk factors
1 mipi MIPI Mantle Cell Lymphoma International Prognostic Index.
2   mipi-n MIPI Niedrig Low risk MIPI score
2   mipi-i MIPI Intermediär Intermediate risk MIPI score
2   mipi-h MIPI Hoch High risk MIPI score
1 risikogruppen-ghsg Risikogruppen GHSG German Hodgkin Study Group risk stratification.
2   risikogruppen-ghsg-fr GHSG Frühe Early favorable risk group
2   risikogruppen-ghsg-i GHSG Intermediär Intermediate risk group
2   risikogruppen-ghsg-fo GHSG Fortgeschritten Advanced risk group
1 ipss IPSS International Prognostic Scoring System for myelodysplastic syndromes.
2   ipss-l IPSS Low Low risk: score 0
2   ipss-i1 IPSS Intermediate-I Intermediate-1 risk: score 0.5-1.0
2   ipss-i2 IPSS Intermediate-II Intermediate-2 risk: score 1.5-2.0
2   ipss-h IPSS High risk High risk: score ≥2.5
1 her2-neu HER2-neu HER2-neu protein expression and gene amplification status.
2   her2-neu-p HER2-neu Positiv Positive HER2-neu status (IHC 3+ or FISH amplified)
2   her2-neu-n HER2-neu Negativ Negative HER2-neu status (IHC 0-1+ or FISH not amplified)

Description of the above table(s).